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Purpose/Objective: The Esteya® electronic brachytherapy 
system (Elekta Brachytherapy, The Netherlands) has been 
recently developed for HDR brachytherapy treatment of skin 
lesions, using a 69.5 kVp X-ray source. The purpose of this 
study was to evaluate the surface dose rate of the Esteya by 
using different detectors and calibration protocols. Results 
are compared considering the uncertainty of each method. 
Materials and Methods: The surface dose rates of the 15, 20, 
25 and 30 mm diameter applicators of Esteya were measured 
with the plane parallel ionization chamber T34013 (PTW-
Freiburg, Germany) and the parallel plate ionization chamber 
Exradin A20 (Standard Imaging Inc., USA). The first one was 
calibrated in both air and water, whereas the second one was 
provided with calibration in air. Measurements in air were 
performed according to dosimetric protocol established by 
the Task Group 61 of the American Association of Physicists in 
Medicine, whereas measurements in water were performed in 
a CIRS Plastic Water® phantom, using the methodology 
proposed by the International Atomic Energy Agency in its 
report TRS-398. Measurements were corrected by the 
effective point of measurement in each case. 
Results: Table 1 shows the relative differences between the 
experimental measurements of this study and the internal 
values used by Esteya to determine the treatment times. The 
relative uncertainty (with coverage factor k = 1) of the 
absorbed dose measurements are: 2.5% for the T34013 
chamber calibrated in water, 2.7% for the T34013 chamber 
calibrated in air, and 2.6% for the A20 chamber calibrated in 
air. Relative differences between the output factors 
measured in air with the ionization chamber T34013 and the 
A20 are below 2%, which are lower than the uncertainties of 
the dose measurements, so the stem effect of the PTW 
chamber can be considered to be negligible for this 
application. 
Conclusions: The two ionization chambers and the two 
dosimetric protocols have been shown to provide consistent 
results with the internal values from Esteya, considering the 
uncertainties. Further investigation is needed to evaluate the 
equivalence between plastic water and liquid water. Because 
measurements in air require more correction factors and 
because the experimental setup used with solid plastic is 
more similar to the real patient setup, measurements with a 
chamber calibrated in water seem to provide a more direct 
methodology to characterize dosimetrically the Esteya 
system.  
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Purpose/Objective: To test the hypothesis that radiotherapy 
(RT) of head and neck squamous cell carcinoma (HNSCC) can 
be improved by hypoxic modification using nimorazole (NIM) 
in association with accelerated fractionation. 
Materials and Methods: The IAEA-HypoX protocol was 
activated March 2012 as an international multicentre 
randomized trial in patients with HNSCC. The tumour was 
treated to a dose of 66-70 Gy, 33-35 fractions, 6 fractions per 
week. NIM was administered as a total dose of 1.2 g per m2 
body surface area, 90 minutes before the first daily RT 
fraction. The primary endpoint was loco-regional failure. The 
analysis was perfor-med as intention to treat among 
evaluable patients. The trial was closed prematurely by June 
2014 due to insufficient recruitment. This was caused by 
inability to obtain the approval for using the drug in three 
major centres and an insufficient recruitment rate in the 
active participating centres. An associated quality assurance 
program was performed to insure the consistency with the 
protocol guidelines. 
Results: The trial was dimensioned to include 600 patients in 
3 years, but between March 2012 and May 2014 only 104 
patients were randomized. All 20 patients from two centres 
had to be excluded from the final analysis due to the 
unavailability of the follow-up data. Thus, only four of nine 
centres originally planned to participate did contribute to the 
study.  
Among the 84 eligible patients, 2 patients did not start RT 
after randomization. The remaining 82 patients were 
evaluable (39 and 43 patients in the RT+NIM and the RT-alone 
arms, respectively). The treatment compliance was good 
with only six patients not completing the full planned 
radiotherapy course, and with 32 patients (82%) out of 39 
allocated for nimorazole, achieved at least 75% of the 
prescribed drug dose. The cause of failure to fulfil the 
treatment was mainly due to the acute side effects.  
At the time of evaluation, 36 patients had failed to achieve 
persistent loco-regional control, and a total of 40 patients 
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had died. The use of nimorazole improved the loco-regional 
tumour control with an 18 months post-randomisation 
cumulative failure rate of 31% versus 54% in the control 
group, yielding a risk difference of 23% (CI 2%-45%; P= 0.03). 
The corresponding values for overall death was 39% versus 
68%; risk difference 28% (CI 4%-52%; P= 0.02).  
Conclusions: Although the trial was incomplete and suffered 
from small and incomplete number of patients, did the 
analysis indicate a loco-regional control and survival benefit 
in patients given the hypoxic modifier nimorazole in addition 
to accelerated fractionation for advanced HNSCC. 
However, the trial also revealed that conducting multicenter 
and multinational clinical studies combining drug and 
radiotherapy in developing countries, may suffer from 
uncontrolled and unsolvable problems. 
  
OC-0188   
IAEA randomised study on optimization of treatment of 
locally advanced NSCLC using radiotherapy and 
chemotherapy 
B. Jeremic1, E. Fidarova2, V. Sharma3, M. Faheem4, A. 
Ameira5, C. Nasr Ben Amar6, A. Frobe7, F.N. Lau8, S. Brincat9, 
G. Jones10 
1Institute for Pulmonary Diseases of Vojvodina, 
Radiotherapy, Sremska Kamenica, Serbia  
2International Atomic Energy Agency, NAHU/ARBR, Vienna, 
Austria  
3University of Witswatersrand, Radiation Oncology, 
Johannesburg, South Africa  
4Nuclear Medicine Oncology and Radiotherapy, Radiotherapy, 
Islamabad, Pakistan  
5Misr Oncology Centre, Oncology, Cairo, Egypt  
6Institut National de Cancer Salah Aziz, Radiotherapy, Tunis, 
Tunisia  
7"Sestre Milosrdnice" Clinical Hospital, Radiotherapy, Zagreb, 
Croatia  
8General Hospital Kuala Lumpur, Radiotherapy and Oncology,  
Kuala Lumpur, Malaysia  
9Sir Paul Boffa Hospital, Radiotherapy and Oncology, Floriana 
VLT, Malta 
10Credit Valley Hospital, Radiation Oncology, Mississauga, 
Canada  
 
Purpose/Objective: Patients with incurable locally advanced 
non-small cell lung cancer (NSCLC) (mainly Stage IIIB) usually 
receive palliative treatment with either radiotherapy (RT) 
alone (39 Gy in 13 fractions or 10-17 Gy in 1-2 fractions) or 
several cycles of doublet chemotherapy (CHT) regimens. In 
order to optimize treatment approach in this disease and 
improve access to RT in limited resource setting, 
International Atomic Energy Agency conducted a prospective 
randomised study (NCT00864331) comparing protracted RT 
course with CHT followed by one or two fractions of RT. 
Materials and Methods: Total of 65 patients from 7 
institutions aged ≥ 18 years, with histologically confirmed 
NSCLC, stage IIIA/IIIB, Karnofsky performance status (KPS) 60-
90, previously not treated for NCSLC were randomised, 31 to 
arm A and 34 to arm B. Exclusion criteria were RT field > 200 
cm2 and pregnancy. In arm A, RT consisted of 39 Gy in 13 
fractions. In arm B, 2 to 3 platinum-based CHT cycles were 
prescribed, and were followed by 10 Gy given in a single 
fraction or 16 Gy given in 2 fractions separated by one week. 
Further treatments depended on disease progression and 
patient condition and were left to the discretion of involved 
radiation oncologist. Primary outcome was overall survival.  
Results: Treatment groups were balanced with respect to 
various variables (Table 1). Treatment compliance was also 
given in Table 1.  
 
With follow-up through Feb 2014, 6/65 remained alive, 3 in 
each arm (all 6 being lost to follow-up at > 1 yr of 
observation). Median survival for all 65 patients was 0.66 yr 
(maximum 5.0 yr), while median survival was 0.59 and 0.68 
yr for the two arms, respectively (log-rank p=0.4 by study 
arm, and p=0.6 by Cox regression, stratified by country and 
sub-stage). One- to three-year survival rates for the two arms 
were 29%, 9% and 9% vs 41%, 12% and 6%, respectively) 
(Figure 1). 
  
There was no difference in any of the following endpoints (all 
values, p>0.5): any failure, occurring in 26 cases each in A 
and B; local failure, occurring in 18 cases each; regional 
failure, occurring in 6 and 8 cases in the two arms, 
respectively; contra-lateral thoracic disease, occurring in 3 
cases each; and distant failure, occurring in 13 and 14 cases 
in the two arms, respectively. Post-initial treatment, in arm 
A more courses of palliative RT were administered (17 
courses in 11 cases, vs. 4 in 4 cases in arm B), along with 
slightly more palliative CHT cycles (19 cycles in 7 cases, vs. 
11 in 2 cases in arm B).  
Conclusions: There were no differences in survival, relapse 
patterns and symptoms between the two arms. When 
compared to high-dose palliative RT, CHT followed by one or 
two fractions of RT produced similar results. It can be 
recommended as treatment approach, especially in limited 
resource setting, where access to RT remains inadequate.  
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